These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 9259085)
21. De novo muscle invasive bladder cancer: is there a change in trend? Vaidya A; Soloway MS; Hawke C; Tiguert R; Civantos F J Urol; 2001 Jan; 165(1):47-50; discussion 50. PubMed ID: 11125361 [TBL] [Abstract][Full Text] [Related]
22. Diagnosis of Bladder Carcinoma: A Clinician's Perspective. Harshman LC; Preston MA; Bellmunt J; Beard C Surg Pathol Clin; 2015 Dec; 8(4):677-85. PubMed ID: 26612221 [TBL] [Abstract][Full Text] [Related]
23. Pathology and its importance in evaluating outcome in patients with superficial bladder cancer. Huben RP; Gaeta J Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):23-9. PubMed ID: 8727807 [TBL] [Abstract][Full Text] [Related]
24. Management of high-risk non-muscle invasive bladder cancer. Brausi M; Olaru V Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212 [TBL] [Abstract][Full Text] [Related]
25. Visualization of the basement membrane zone of the bladder by optical coherence tomography: feasibility of noninvasive evaluation of tumor invasion. Hermes B; Spöler F; Naami A; Bornemann J; Först M; Grosse J; Jakse G; Knüchel R Urology; 2008 Sep; 72(3):677-81. PubMed ID: 18455778 [TBL] [Abstract][Full Text] [Related]
26. Therapeutic efficacy of salvage cystectomy. Do results reflect natural history of bladder cancer? Droller MJ; Walsh PC Urology; 1983 Aug; 22(2):118-22. PubMed ID: 6879880 [TBL] [Abstract][Full Text] [Related]
28. [Diagnosis and substaging of pT1 bladder cancer]. Cheng L; Huang WB; Zheng SQ; Zheng J Zhonghua Bing Li Xue Za Zhi; 2007 Sep; 36(9):636-9. PubMed ID: 18070458 [No Abstract] [Full Text] [Related]
29. Alternatives to cytology in the management of non-muscle invasive bladder cancer. Amiel GE; Shu T; Lerner SP Curr Treat Options Oncol; 2004 Oct; 5(5):377-89. PubMed ID: 15341676 [TBL] [Abstract][Full Text] [Related]
30. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach. Otto W; Breyer J; Herdegen S; Eder F; Bertz S; May M; Mayr R; Lausenmeyer EM; Denzinger S; van Rhijn BW; Burger M; Hartmann A Int Urol Nephrol; 2017 Mar; 49(3):431-437. PubMed ID: 28035618 [TBL] [Abstract][Full Text] [Related]
31. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association. Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T; Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609 [TBL] [Abstract][Full Text] [Related]
32. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Shariat SF; Weizer AZ; Green A; Laucirica R; Frolov A; Wheeler TM; Lerner SP Urology; 2000 Nov; 56(5):735-40. PubMed ID: 11068290 [TBL] [Abstract][Full Text] [Related]
33. Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma. Kumar P; Nandi S; Tan TZ; Ler SG; Chia KS; Lim WY; Bütow Z; Vordos D; De la Taille A; Al-Haddawi M; Raida M; Beyer B; Ricci E; Colombel M; Chong TW; Chiong E; Soo R; Park MK; Ha HK; Gunaratne J; Thiery JP Oncotarget; 2015 May; 6(15):13539-49. PubMed ID: 25915536 [TBL] [Abstract][Full Text] [Related]
34. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. Byrne RR; Shariat SF; Brown R; Kattan MW; Morton RA JR; Wheeler TM; Lerner SP J Urol; 2001 May; 165(5):1473-9. PubMed ID: 11342899 [TBL] [Abstract][Full Text] [Related]
35. Diagnosis and management of superficial bladder cancer. Soloway MS Semin Surg Oncol; 1989; 5(4):247-54. PubMed ID: 2549605 [TBL] [Abstract][Full Text] [Related]
36. [Bladder tumor histo-seminar - case 6: Invasive urothelial carcinoma, with inverted growth (UroA/FGFR3 molecular type)]. Allory Y Ann Pathol; 2016 Dec; 36(6):394-397. PubMed ID: 27838079 [No Abstract] [Full Text] [Related]
37. Diagnosis and treatment of superficial transitional cell carcinoma of the bladder: facts and perspectives. Kurth KH Eur Urol; 1997; 31 Suppl 1():10-9. PubMed ID: 9076481 [TBL] [Abstract][Full Text] [Related]
38. Overstaging of transitional cell carcinoma: clinical significance of lamina propria fat within the urinary bladder. Bochner BH; Nichols PW; Skinner DG Urology; 1995 Mar; 45(3):528-31. PubMed ID: 7879346 [TBL] [Abstract][Full Text] [Related]
39. An organ-preserving approach to muscle-invading transitional cell cancer of the bladder. Brown AL; Zietman AL; Shipley WU; Kaufman DS Hematol Oncol Clin North Am; 2001 Apr; 15(2):345-58, vii. PubMed ID: 11370497 [TBL] [Abstract][Full Text] [Related]
40. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. Bol MG; Baak JP; Buhr-Wildhagen S; Kruse AJ; Kjellevold KH; Janssen EA; Mestad O; Øgreid P J Urol; 2003 Apr; 169(4):1291-4. PubMed ID: 12629345 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]